Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Yehia, Sameh"'
Autor:
Yehia, Sameh1 s.yehia@suezuni.edu.eg, El-Baky, Sayed Abd2 s_elbakey@yahoo.com, Haded, Abdullah3 ab.t@hotmail.com, Ibrahim, Arafa M. A.4 arafamai2015@gmail.com
Publikováno v:
Journal of Engineering Sciences. Sep/Oct2023, Vol. 51 Issue 5, p318-342. 25p.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Advances in Structural Engineering. Sep2021, Vol. 24 Issue 12, p2826-2840. 15p.
Publikováno v:
Practice Periodical on Structural Design & Construction; Nov2023, Vol. 28 Issue 4, p1-11, 11p
Publikováno v:
Innovative Infrastructure Solutions; 10/13/2023, Vol. 8 Issue 11, p1-14, 14p
Publikováno v:
Fayoum University Medical Journal. 8:21-31
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7c092046b732bca27c643c25782c246
https://doi.org/10.21608/fumj.2021.184726
https://doi.org/10.21608/fumj.2021.184726
Publikováno v:
International Review of Civil Engineering; May2023, Vol. 14 Issue 3, p164-174, 11p
Autor:
Hisham R El-Khayat, Alaa Hasseb, Yehia Sameh, Maissa El Raziky, Dina Attia, Wahid Doss, Hani Mahmoud, Yasser Fouad, Bassel Ebeid, Magdy El Serafy, Ahmed A. Gomaa, Enas M Kamal, Gamal Esmat
Publikováno v:
European journal of gastroenterologyhepatology. 32(3)
BACKGROUND Nonstructural protein 5A (NS5A) is an important regimen for the treatment of chronic hepatitis C virus (HCV) genotype-4 infected patients. Retreatments for NS5A virologic failure are limited. The aim of this study is to provide real-life d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0ead20b3c1e649641ac86ca1f149d87
https://pubmed.ncbi.nlm.nih.gov/31688311
https://pubmed.ncbi.nlm.nih.gov/31688311
Autor:
Mortada El-Shabrawi, Enas M Kamal, Dina Attia, Hisham R El-Khayat, Mostafa Yakoot, Yehia Sameh, Yasser Fouad
Publikováno v:
Liver international : official journal of the International Association for the Study of the LiverREFERENCES. 40(2)
Background & aims Treatment of children aged 3-6 genotype 4 is still limited by the interferon side effects. We aimed in this study to evaluate the effectiveness and safety of sofosbuvir/ledipasvir in children (3-6 years) genotype 4 chronic HCV-infec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::212a2a812e43eb2c5148530f97c7a150
https://pubmed.ncbi.nlm.nih.gov/31967401
https://pubmed.ncbi.nlm.nih.gov/31967401
Autor:
Alaa Farouk Haseeb, Manal M Abdel Gawad, Naglaa M. Kamal, Mortada El Shabrawi, Hesham El-Khayat, Yasser Fouad, Mostafa Yakoot, Enas M Kamal, Yehia Sameh, Dina Attia
Publikováno v:
European journal of gastroenterologyhepatology. 31(8)
Background The sustained virological response (SVR) rate for the 12-week sofosbuvir (SOF)/ledipasvir (LVD) treatment of adolescent genotype-4 patients is high. The aim of this study is to evaluate 8 versus 12-week treatment efficacy and safety in ado
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5928649d1ee03f95b6def993028d57cd
https://pubmed.ncbi.nlm.nih.gov/30676473
https://pubmed.ncbi.nlm.nih.gov/30676473